Saturday 17 October 2026
Export HELP’s income statement to Excel — free account
Cybin Inc.
HELP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.3% and free cash flow fell 25.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.55
0.50
−4.52%
Follow HELP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 49.99 | 2.96 | 36.10 | 10.07 | 7.98 | 6.50 | 4.81 | 3.76 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | 49.99 | 74.63 | 128.44 | 46.36 | 28.04 | 19.84 | 10.73 | 15.15 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 38 | 38 | 50 | 50 | 50 | 100 | ||||
| Revenue/emp, $m | — | — | — | — | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 23.15 | 0.00 | 0.00 | — | — | — | |||||
| EBT | 0 | 0 | 0 | — | (24) | (54) | (36) | (58) | (82) | (148) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | — | (3,729.31) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | 0 | 0 | 0 | — | (24) | (54) | (36) | (58) | (82) | (148) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | — | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (0.01) | (0.02) | (0.01) | — | (9.51) | (12.17) | (7.22) | (7.22) | (4.02) | (4.25) | |||||
| Cash flow | 0.00 | (0.02) | 0.00 | — | (5.48) | (8.20) | (7.36) | (6.16) | (3.58) | (3.83) | |||||
| Capex | 0.00 | 0.00 | 0.00 | — | (0.07) | (0.09) | (0.51) | (0.06) | (0.07) | (0.04) | |||||
| Free cash flow | 0.00 | (0.02) | 0.00 | — | (5.55) | (8.29) | (7.87) | (6.22) | (3.65) | (3.87) | |||||
| Book value | 0.02 | 0.03 | 0.02 | — | 24.81 | 13.81 | 7.48 | 26.10 | 8.16 | 6.66 | |||||
| Shares, m | 14 | 12 | 14 | — | 3 | 4 | 5 | 8 | 20 | 35 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| P/B | — | — | — | — | 87.26 | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | (399.06) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | 0 | — | (14) | (36) | (36) | (51) | (72) | (133) | ||||
| Capex | 0 | 0 | 0 | — | 0 | 0 | (3) | (1) | (1) | (1) | |||||
| Free cash flow | 0 | 0 | 0 | — | (15) | (36) | (38) | (52) | (74) | (135) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 0 | 0 | 0 | — | 47 | 40 | 13 | 155 | 101 | 165 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | 0 | 0 | 0 | — | (49) | (43) | (13) | (155) | (94) | (157) | |||||
| Shareholders’ equity | 0 | 0 | 0 | — | 65 | 61 | 36 | 216 | 165 | 232 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (27.85) | (49.89) | (22.78) | — | (69.65) | (78.84) | (66.63) | (43.74) | (40.42) | (68.67) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | — | (86.35) | (177.22) | (101.89) | (59.41) | (90.68) | (119.57) | |||||
| ROE | (34.07) | (61.02) | (23.59) | — | (74.49) | (85.63) | (73.89) | (45.77) | (42.79) | (74.60) | |||||
Negative figures in brackets.
Fiscal years to Mar 2021
Charts ten years each
Cybin Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| VSTM Verastem, Inc. | $835.9M | — (loss-making) | — (loss-making) | +1,775.43% (above 0%: growing) | n/m | −34.43% (below 0%: shrinking) | 89.92% | (81.62%) | Compare |
| CRVS Corvus Pharmaceuticals, Inc. | $828.6M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVBP ArriVent BioPharma, Inc. | $827.9M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| ARDX Ardelyx, Inc. | $814.9M | — (loss-making) | — (loss-making) | +23.77% (above 0%: growing) | n/m | +75.33% (above 0%: growing) | 95.24% | (10.28%) | Compare |
| HELP Cybin Inc. | $807.3M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | |
| DNA Ginkgo Bioworks Holdings, Inc. | $791.9M | — (loss-making) | — (loss-making) | −48.49% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| GERN Geron Corporation | $790.2M | — (loss-making) | — (loss-making) | +17.22% (above 0%: growing) | n/m | +41.82% (above 0%: growing) | 83.92% | (21.74%) | Compare |
| Median of peers | $828.2M | — | — | +20.50% | — | −25.40% | 91.47% | (51.68%) |
Cybin Inc. (HELP) key facts
- Cybin Inc. (HELP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HELP traded at $10.55, a market capitalization of $807.3 million.
- Return on equity was −74.6% and debt-to-equity 0.00.